SNS-314
Based on 3 publication(s) in Google Scholar
SNS-314 is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively.
For research use only. We do not sell to patients.
- CAS No.: 1057249-41-8
- Formula: C18H15ClN6OS2
- Molecular Weight:430.93
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10127
BarasertibAurora B Inhibitor -
HY-13253
AMG 900Aurora Kinase Inhibitor -
HY-10126
Barasertib-HQPAAurora B Inhibitor -
HY-12201
TAK-901 -
HY-10971
AlisertibAurora A Kinase Inhibitor -
HY-10179
DanusertibAurora Kinase Inhibitor -
HY-70044
GSK-1070916Aurora B/C Inhibitor -
HY-12054
HesperadinAurora B Inhibitor -
HY-10180
MLN8054Aurora A Inhibitor -
HY-10161
TozasertibAurora A/B/C Inhibitor -
HY-13252
MK-5108Aurora Kinase Inhibitor -
HY-10804
CCT 137690Apoptosis Inducer
Publications Citing Use of MedChemExpress (MCE) SNS-314
MoreAll Aurora Kinase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Aurora A 9 nM (IC50) |
Aurora B 31 nM (IC50) |
Aurora C 6 nM (IC50) |
In Vitro
SNS-314 blocks proliferation in a broad panel of tumor cell lines (HCT116, A2780, PC-3, HeLa, MDA-MB-231, H-1299, and HT29) with IC50 values ranging from 1.8 nM in A2780 ovarian cancer cells to 24 nM in HT29 colon cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1057249-41-8
-
Molecular Weight 430.93
-
Formula C18H15ClN6OS2
-
SMILES
O=C(NC1=NC=C(CCNC2=C3C(C=CS3)=NC=N2)S1)NC4=CC=CC(Cl)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Int J Mol Sci
2026 Mar 11;27(6):2587. PMID: 41898448 -
Purity & Documentation
References
[1]. Oslob JD, et al. Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4. [Content Brief]
[2]. Arbitrario JP, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SNS-314 Related Classifications
HY-108344 Related Classifications
Powered by Bioz